TaiGen Biopharmaceuticals Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

TaiGen Biopharmaceuticals Holdings şirketinin toplam hissedar öz sermayesi NT$1.1B ve toplam borcu NT$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla NT$1.2B ve NT$108.9M dir.

Anahtar bilgiler

Borç/özkaynak oranı

NT$0

Borç

Faiz karşılama oranı	n/a
Nakit	NT$1.06b
Eşitlik	NT$1.11b
Toplam yükümlülükler	NT$108.94m
Toplam varlıklar	NT$1.22b

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Situation

Apr 19

We're Not Very Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Rate

Jan 04

Recent updates

Here's Why We're Not Too Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Situation

Apr 19

We're Not Very Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Rate

Jan 04

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4157 'nin kısa vadeli varlıkları ( NT$1.1B ) kısa vadeli yükümlülüklerini ( NT$58.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: 4157 şirketinin kısa vadeli varlıkları ( NT$1.1B ) uzun vadeli yükümlülüklerini ( NT$50.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4157 borçsuzdur.

Borcun Azaltılması: 4157 un 5 yıl önce borcu yoktu.

Borç Kapsamı: 4157 un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 4157 şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

TaiGen Biopharmaceuticals Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why We're Not Too Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Situation

We're Not Very Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Rate

Recent updates

Third quarter 2024 earnings released: NT$0.10 loss per share (vs NT$0.012 loss in 3Q 2023)

Second quarter 2024 earnings released: EPS: NT$0.09 (vs NT$0.014 in 2Q 2023)

First quarter 2024 earnings released: NT$0.01 loss per share (vs NT$0.07 loss in 1Q 2023)

Full year 2023 earnings released: EPS: NT$0.19 (vs NT$0.33 loss in FY 2022)

TaiGen Biopharmaceuticals Holdings Limited, Annual General Meeting, May 29, 2024

Third quarter 2023 earnings released: NT$0.01 loss per share (vs NT$0.015 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: NT$0.015 (vs NT$0.14 loss in 2Q 2022)

Full year 2022 earnings released: NT$0.33 loss per share (vs NT$1.08 profit in FY 2021)

Third quarter 2022 earnings released: EPS: NT$0.02 (vs NT$0.20 loss in 3Q 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: NT$0.02 (vs NT$0.20 loss in 3Q 2021)

Second quarter 2022 earnings released: NT$0.14 loss per share (vs NT$1.54 profit in 2Q 2021)

Investor sentiment improved over the past week

First quarter 2022 earnings released: NT$0.05 loss per share (vs NT$0.061 loss in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: NT$1.08 (vs NT$0.56 loss in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: NT$0.19 loss per share (vs NT$0.14 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$1.54 (vs NT$0.14 loss in 2Q 2020)

First quarter 2021 earnings released: NT$0.06 loss per share (vs NT$0.10 loss in 1Q 2020)

Here's Why We're Not Too Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Situation

Full year 2020 earnings released: NT$0.56 loss per share (vs NT$0.41 loss in FY 2019)

TaiGen Biopharmaceuticals Holdings Limited, Annual General Meeting, May 27, 2021

New 90-day low: NT$17.90

New 90-day low: NT$21.35

We're Not Very Worried About TaiGen Biopharmaceuticals Holdings' (GTSM:4157) Cash Burn Rate

TaiGen Biotechnology Company, Limited Partners with GPCR Therapeutics, Inc. to Develop Burixafor & Taigexyn(R)

Third quarter 2020 earnings released: NT$0.14 loss per share

First half earnings released

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin